Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 14:53:34 04/07/2024 BST			5-day change	1st Jan Change
97.18 ^CHF	+1.12%		+1.78%	+14.47%

07-03	NOVARTIS AG : Berenberg sticks Neutral	ZD
07-02	Carisma Therapeutics Notifies Novartis Pharmaceuticals of Terminated Manufacturing, Supply Agreement	DJ

NOVARTIS AG : Deutsche Bank reiterates its Buy rating

July 02, 2024 at 12:24 pm

In a research note published by Emmanuel Papadakis, Deutsche Bank advises its customers to buy the stock. The target price is unchanged and still at CHF 110.

Latest news about Novartis AG

NOVARTIS AG : Berenberg sticks Neutral	07-03	ZD
Carisma Therapeutics Notifies Novartis Pharmaceuticals of Terminated Manufacturing, Supply Agreement	07-02	DJ
NOVARTIS AG : Receives a Buy rating from Jefferies	07-02	ZD
NOVARTIS AG : Deutsche Bank reiterates its Buy rating	07-02	ZD
Fitch Affirms Novartis Ratings on Leading Position in Innovative Pharmaceutical Sector	07-02	MT
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments	07-01	MT
New semester, new state of mind	07-01
NOVARTIS AG : Gets a Buy rating from Goldman Sachs	07-01	ZD
Foreign banks target Switzerland after UBS takeover of Credit Suisse	06-24	RE
NOVARTIS AG : Barclays reaffirms its Sell rating	06-24	ZD
INDEX-MONITOR: Tui, Rational and Traton in the MDax - Douglas moves up to the SDax	06-24	DP
Factbox-European companies cut jobs as economy sputters	06-21	RE
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15	06-20	DP
Novartis: towards the filing of a buyout offer for MorphoSys	06-20	CF
MorphoSys Set to Delist Following Acquisition by Novartis	06-20	MT
MorphoSys Inks Delisting Agreement After Takeover by Novartis	06-20	MT
Biotech company Morphosys will soon disappear from the stock exchange	06-20	RE
EU regulator mandates label updates on CAR-T cancer therapies	06-14	RE
PeptiDream and Novartis Agreement Becomes Effective with 28.3 Billion Yen Upfront Payment	06-14	MT
Nkarta, Inc. Appoints George Vratsanos as Board of Directors	06-13	CI
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment	06-13	CI
NOVARTIS AG : JP Morgan reiterates its Neutral rating	06-11	ZD
Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy	06-07	MT
Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug	06-07	MT
AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation	06-06	MT

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

18/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 06:24 pm

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 12:18 pm

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 03:32 pm

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

106.7 USD

Average target price

110.3 USD

Spread / Average Target

+3.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+14.47%	218B
ELI LILLY AND COMPANY	+54.07%	809B
NOVO NORDISK A/S	+39.05%	621B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	319B
ABBVIE INC.	+5.72%	289B
ASTRAZENECA PLC	+14.62%	238B
ROCHE HOLDING AG	-0.70%	221B
AMGEN INC.	+7.42%	166B
PFIZER, INC.	-3.79%	157B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : Deutsche Bank reiterates its Buy rating

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals